Correlative results from NCI CTEP/ETCTN 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for advanced conventional chondrosarcoma (cCS).Kristine Peregrino Lacuna, Mia C. Weiss, Mihaela Druta et al.|Journal of Clinical Oncology|2024Cited by 3
A phase II trial with safety lead-in to evaluate the addition of sotigalimab, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sarcoma.Sminu Bose, Matthew Ingham, Liner Ge et al.|Journal of Clinical Oncology|2023Cited by 2
ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma.Kristine Peregrino Lacuna, Matthew Ingham, Shing M. Lee et al.|Journal of Clinical Oncology|2023Cited by 1